Hong Kong, China recently announced that all products containing cannabidiol (CBD) will be banned starting February 1st. CBD will be added to the Dangerous Drugs Ordinance (DDO), which already includes over 200 substances such as fentanyl, ketamine, heroin, and various psychoactive compounds like MDMA.
CBD will now be included in the existing list of "cannabinol and its tetrahydro derivative (THC); as well as 3-alkyl homologues." As a result of this change, anyone who possesses or consumes CBD will face a maximum of seven years in prison and a fine of up to HKD 1 million (approximately RMB 870,000).
According to Lexology, manufacturers of CBD may also face life imprisonment.
Although many users around the world have been touting the anti-anxiety and pain-relieving properties of CBD, the Hong Kong Security Bureau believes that these claims "lack authoritative scientific evidence." This directive appears to be consistent with China's ban on the use of CBD in cosmetics implemented last year.
Currently, it is unclear whether other cannabinoids such as CBG, CBDV, CBC, etc. will be included in the ban. However, based on a memorandum from the Narcotics Division in November 2022, the Hong Kong government appears to be primarily concerned about the possibility of CBD products containing trace amounts of THC, either through breakdown or conversion, and the lack of international regulations specifically for these products.
Article Related Reading: Hong Kong plans to completely ban the sale of CBD products by the end of 2022.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
